NCT01435213已完成1 期
Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Receptor occupancy
研究概览
简要总结
The purpose of this study is to validate [11C]ORM-13070 as an alpha2C-adrenoceptor imaging agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor occupancy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written informed consent (IC) obtained.
- •Good general health ascertained by detailed medical history, laboratory investigations and physical examination.
- •Males between 20 and 40 years of age (inclusive).
- •Body mass index (BMI) between 18-28 kg/m2 inclusive (BMI = weight/height2).
- •Weight 60-100 kg (inclusive).
排除标准
- •Suspected poor compliance with the protocol or inability to communicate well with the study personnel.
- •Veins unsuitable for repeated venipuncture.
- •CYP2D6 slow metabolizer or ultrarapid metabolizer genotype.
- •Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.
- •Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
- •Susceptibility to severe allergic reactions.
- •Intake of any medication that could affect the outcome of the study, within 2 weeks prior to the tracer administration (2 months for enzyme inducing drugs like rifampicin or carbamazepine), or less than 5 times the half-life of the medication.
- •Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits, about 13 g of alcohol).
- •Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.
- •Inability to refrain from using nicotine-containing products during the stay at the study centre.
- •Inability to refrain from consuming caffeine-containing beverages during the stay at the study centre, e.g. propensity for headache when refraining from caffeine-containing beverages.
- •Blood donation or loss of significant amount of blood within 2 months prior to the screening visit.
- •Abnormal 12-lead electrocardiogram (ECG) finding of clinical relevance after 10 minutes rest in supine position at the screening visit, for example:
- •QTc (calculated using Bazett's formula) > 450 msec,
- •PR < 120 msec or > 210 msec,
- •QRS < 70 msec or > 120 msec.
- •Heart rate (HR) < 40 beats/minute or > 90 beats/minute after 10 minutes rest in supine position at the screening visit.
- •At the screening visit, systolic blood pressure (BP) < 90 mmHg or > 140 mmHg after 10 minutes in supine position, diastolic BP < 50 mmHg or > 90 mmHg after 10 minutes in supine position.
- •Any abnormal laboratory value, vital sign or physical examination result, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk to the subject if he takes part in the study.
- •History of drug abuse or positive result in drug abuse test.
- •Positive serology to human immunodeficiency virus antibodies (HIVAb), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibodies (HCVAb).
- •Anatomical abnormality in brain MRI which may in the opinion of the investigator interfere with the interpretation of the PET results.
- •Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk to the subject.
- •Participation in another clinical drug study within 3 months prior to this study.
- •Participation in a prior PET study or other medical or occupational exposure to significant doses of ionizing radiation.
- •Any contraindication to MRI of the brain.
研究组 & 干预措施
Atipamezole
Experimental
干预措施: Atipamezole (Drug)
Atomoxetine
Experimental
干预措施: Atomoxetine (Drug)
Ketamine
Experimental
干预措施: Ketamine (Drug)
Insulin-induced hypoglycemia
Experimental
干预措施: Insulin (Drug)
Cold pressor test
Experimental
干预措施: Cold pressor test (Other)
Placebo
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
Receptor occupancy
时间窗: 30 minutes
PET tracer (interventional drug) uptake in the brain is measured for 30 minutes by PET after various pharmacological and physiological pre-treatments.
次要结局
未报告次要终点
研究者
Juha Rinne
Professor
University of Turku
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous NoradrenalineChanges in Striatal [11C]ORM-13070 Binding.NCT01794975University of Turku8
已完成
不适用
Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PETHigh StressObesityAlcohol DependenceNCT01719497Yale University74
终止
不适用
Effects of Nicotine on Brain Opioid ReceptorsNicotine DependenceNCT01040338University of Pennsylvania15
撤回
早期 1 期
PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]ButanolHealthy VolunteersNCT04032691Weill Medical College of Cornell University
已完成
2 期
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTGastrointestinal Stromal Tumor (GIST)NCT01294202Astex Pharmaceuticals, Inc.26